Lotte Bult
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lotte Bult has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Alberta A. H. J. Thiadens
Department of Ophthalmology Erasmus MC University Medical Center Rotterdam the Netherlands
1 shared publication- Anne R. Schlosser
Department of Dermatology Erasmus MC University Medical Center Rotterdam The Netherlands
1 shared publication DirkJan Hijnen
Department of Dermatology Erasmus MC University Medical Center Rotterdam The Netherlands
1 shared publicationGerrit J. Braunstahl
Department of Pulmonology Franciscus Gasthuis and Vlietland Rotterdam The Netherlands
1 shared publication- Gert-Jan Braunstahl
Department of Pulmonology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
1 shared publication J.C. Thelen
Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 16 August 2024
- Published by Wiley in Clinical and Translational Allergy
- Vol. 14 (8) , e12386
Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis
Background: Dupilumab has been shown to be an effective treatment in moderate‐to‐severe atopic dermatitis (AD) and severe asthma (SA). However, comparative real‐world analyses of adverse events (AE), particularly dupilumab‐associated ocular surface disease (DAOSD), are lacking.Objective: This is the first real‐world study to provide insight into the prevalence of AEs associated with dupilumab in AD compared with SA. Secondary objectives were to assess the prevalence, onset and therapeutic strategies of DAOSD and evaluate dupilumab discontinuation rates.Methods: Data from two daily practice registries including AD and SA patients receiving dupilumab treatment were analyzed. Adverse events, including DAOSD, were evaluated.Results: In total, 322 AD and 148 SA patients were included. Headaches (23.6%), injection site reactions (10.1%), and influenza‐like symptoms (13.5%) were more prevalent in SA patients. Interestingly, ocular AEs were significantly more prevalent in AD patients (62.1%, p < 0.001), including conjunctivitis (17.1%, p = 0.004). 88% AD and 47% SA patients with ocular AEs received one or more ophthalmic treatment(s). Additionally, 20% of AD and 17.6% of SA patients discontinued dupilumab treatment due to ocular AEs, while only 65% of these AD and none of these SA patients were referred to an ophthalmologist.Conclusion: The higher incidence of DAOSD in AD patients compared with SA patients in this real‐world study highlights the importance of physician awareness, especially when prescribing dupilumab to AD patients. Conversely, the findings of this study help alleviate potential concerns about ocular AEs in patients with SA who do not have comorbid AD. Furthermore, the effective management of most ocular AEs with ophthalmic treatments suggests favorable tolerability of dupilumab in daily practice, and multidisciplinary collaboration is essential to proactively manage ocular AEs before discontinuing dupilumab.
- 16 August 2024
- Published by Wiley in Clinical and Translational Allergy
- Vol. 14 (8) , e12386
Open AccessHigher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis
Background: Dupilumab has been shown to be an effective treatment in moderate‐to‐severe atopic dermatitis (AD) and severe asthma (SA). However, comparative real‐world analyses of adverse events (AE), particularly dupilumab‐associated ocular surface disease (DAOSD), are lacking.Objective: This is the first real‐world study to provide insight into the prevalence of AEs associated with dupilumab in AD compared with SA. Secondary objectives were to assess the prevalence, onset and therapeutic strategies of DAOSD and evaluate dupilumab discontinuation rates.Methods: Data from two daily practice registries including AD and SA patients receiving dupilumab treatment were analyzed. Adverse events, including DAOSD, were evaluated.Results: In total, 322 AD and 148 SA patients were included. Headaches (23.6%), injection site reactions (10.1%), and influenza‐like symptoms (13.5%) were more prevalent in SA patients. Interestingly, ocular AEs were significantly more prevalent in AD patients (62.1%, p < 0.001), including conjunctivitis (17.1%, p = 0.004). 88% AD and 47% SA patients with ocular AEs received one or more ophthalmic treatment(s). Additionally, 20% of AD and 17.6% of SA patients discontinued dupilumab treatment due to ocular AEs, while only 65% of these AD and none of these SA patients were referred to an ophthalmologist.Conclusion: The higher incidence of DAOSD in AD patients compared with SA patients in this real‐world study highlights the importance of physician awareness, especially when prescribing dupilumab to AD patients. Conversely, the findings of this study help alleviate potential concerns about ocular AEs in patients with SA who do not have comorbid AD. Furthermore, the effective management of most ocular AEs with ophthalmic treatments suggests favorable tolerability of dupilumab in daily practice, and multidisciplinary collaboration is essential to proactively manage ocular AEs before discontinuing dupilumab.
- Open Access
- 9 July 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 231, 107720
Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study
- 9 July 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 231, 107720
Open AccessDupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study